Ossiam Acquires 6,950 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ossiam boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 27.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 32,425 shares of the medical research company’s stock after buying an additional 6,950 shares during the period. Ossiam’s holdings in Edwards Lifesciences were worth $2,683,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of EW. Moneta Group Investment Advisors LLC boosted its holdings in Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Norges Bank acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $658,390,000. Alliancebernstein L.P. increased its position in shares of Edwards Lifesciences by 27.5% in the fourth quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock valued at $1,632,040,000 after acquiring an additional 4,712,819 shares during the last quarter. Two Sigma Advisers LP grew its stake in Edwards Lifesciences by 161.5% in the fourth quarter. Two Sigma Advisers LP now owns 3,503,803 shares of the medical research company’s stock valued at $261,419,000 after purchasing an additional 2,164,100 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Edwards Lifesciences by 655.9% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock valued at $173,502,000 after buying an additional 2,017,801 shares during the last quarter. 79.25% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. TheStreet lowered shares of Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th. Piper Sandler reduced their price target on Edwards Lifesciences from $88.00 to $83.00 and set a “neutral” rating for the company in a report on Friday. Robert W. Baird initiated coverage on Edwards Lifesciences in a research report on Tuesday, July 18th. They issued an “outperform” rating and a $107.00 price objective for the company. Truist Financial increased their price target on Edwards Lifesciences from $101.00 to $105.00 in a research note on Wednesday, July 19th. Finally, StockNews.com initiated coverage on shares of Edwards Lifesciences in a report on Thursday, August 17th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $92.42.

Edwards Lifesciences Stock Performance

EW opened at $74.07 on Monday. The company has a market cap of $45.03 billion, a price-to-earnings ratio of 32.77, a PEG ratio of 4.11 and a beta of 1.03. The company has a current ratio of 3.15, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $98.35. The company’s fifty day moving average price is $83.10 and its two-hundred day moving average price is $84.14.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.65 by $0.01. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.51 billion. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.63 earnings per share. On average, analysts expect that Edwards Lifesciences Co. will post 2.55 EPS for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $93.27, for a total value of $676,673.85. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,795,260.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $93.27, for a total value of $676,673.85. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,795,260.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $76.69, for a total transaction of $115,035.00. Following the completion of the sale, the vice president now owns 23,950 shares in the company, valued at $1,836,725.50. The disclosure for this sale can be found here. Insiders sold 174,859 shares of company stock worth $14,541,940 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.